Is ARTV or IBIO more profitable?

Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -53.86% -48.16% iBio N/A -53.86% -46.48%

Does the media refer more to ARTV or IBIO?

In the previous week, Artiva Biotherapeutics had 1 more articles in the media than iBio. MarketBeat recorded 3 mentions for Artiva Biotherapeutics and 2 mentions for iBio. iBio's average media sentiment score of 0.27 beat Artiva Biotherapeutics' score of 0.22 indicating that iBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral iBio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, SRZN or IBIO?

iBio has lower revenue, but higher earnings than Surrozen. iBio is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Surrozen $3.48M 80.04 -$242.03M -$40.55 N/A iBio $300K 236.80 -$18.38M -$0.58 N/A

Is SRZN or IBIO more profitable?

iBio has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Surrozen's return on equity of 0.00% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets Surrozen -2,885.33% N/A -93.62% iBio N/A -53.86% -46.48%

Does the media favor SRZN or IBIO?

In the previous week, Surrozen had 1 more articles in the media than iBio. MarketBeat recorded 3 mentions for Surrozen and 2 mentions for iBio. Surrozen's average media sentiment score of 0.33 beat iBio's score of 0.27 indicating that Surrozen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral iBio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, CLLS or IBIO?

iBio has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectis $79.59M 4.29 -$67.59M -$0.65 N/A iBio $300K 236.80 -$18.38M -$0.58 N/A

Is CLLS or IBIO more profitable?

iBio has a net margin of 0.00% compared to Cellectis' net margin of -102.34%. iBio's return on equity of -53.86% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets Cellectis -102.34% -94.19% -21.34% iBio N/A -53.86% -46.48%

Does the media prefer CLLS or IBIO?

In the previous week, iBio had 1 more articles in the media than Cellectis. MarketBeat recorded 2 mentions for iBio and 1 mentions for Cellectis. Cellectis' average media sentiment score of 0.30 beat iBio's score of 0.27 indicating that Cellectis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral iBio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IBIO or ELDN more profitable?

iBio's return on equity of -53.86% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% Eledon Pharmaceuticals N/A -149.63% -50.84%

Does the media refer more to IBIO or ELDN?

In the previous week, iBio and iBio both had 2 articles in the media. Eledon Pharmaceuticals' average media sentiment score of 1.35 beat iBio's score of 0.27 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Eledon Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, IBIO or EDIT?

iBio has higher earnings, but lower revenue than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iBio $300K 236.80 -$18.38M -$0.58 N/A Editas Medicine $40.52M 11.79 -$160.06M -$0.75 N/A

Is IBIO or EDIT more profitable?

iBio has a net margin of 0.00% compared to Editas Medicine's net margin of -157.32%. iBio's return on equity of -53.86% beat Editas Medicine's return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -53.86% -46.48% Editas Medicine -157.32% -196.63% -38.17%

Does the media refer more to IBIO or EDIT?

In the previous week, Editas Medicine had 3 more articles in the media than iBio. MarketBeat recorded 5 mentions for Editas Medicine and 2 mentions for iBio. Editas Medicine's average media sentiment score of 0.64 beat iBio's score of 0.27 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Editas Medicine 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

iBio (IBIO) Competitors

$1.43 -0.04 (-2.72%)

As of 08/21/2026 04:00 PM Eastern

Compare

IBIO vs. ARTV, SRZN, CLLS, ELDN, and EDIT

Should you buy iBio stock or one of its competitors? iBio's main competitors and comparable companies include Artiva Biotherapeutics (ARTV), Surrozen (SRZN), Cellectis (CLLS), Eledon Pharmaceuticals (ELDN), and Editas Medicine (EDIT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does iBio compare to Artiva Biotherapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-53.86%	-48.16%
iBio	N/A	-53.86%	-46.48%

In the previous week, Artiva Biotherapeutics had 1 more articles in the media than iBio. MarketBeat recorded 3 mentions for Artiva Biotherapeutics and 2 mentions for iBio. iBio's average media sentiment score of 0.27 beat Artiva Biotherapeutics' score of 0.22 indicating that iBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
iBio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

7.9% of iBio shares are held by institutional investors. 1.8% of Artiva Biotherapeutics shares are held by company insiders. Comparatively, 2.8% of iBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Artiva Biotherapeutics presently has a consensus target price of $39.00, suggesting a potential upside of 256.82%. iBio has a consensus target price of $5.00, suggesting a potential upside of 249.65%. Given Artiva Biotherapeutics' higher possible upside, equities research analysts plainly believe Artiva Biotherapeutics is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Artiva Biotherapeutics has a beta of 2.16, meaning that its stock price is 116% more volatile than the broader market. Comparatively, iBio has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

iBio has higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	2,137.47	-$83.86M	-$3.30	N/A
iBio	$300K	236.80	-$18.38M	-$0.58	N/A

Summary

iBio beats Artiva Biotherapeutics on 10 of the 14 factors compared between the two stocks.

How does iBio compare to Surrozen?

Surrozen (NASDAQ:SRZN) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 31.7% of Surrozen shares are owned by insiders. Comparatively, 2.8% of iBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Surrozen currently has a consensus price target of $45.00, indicating a potential upside of 87.58%. iBio has a consensus price target of $5.00, indicating a potential upside of 249.65%. Given iBio's stronger consensus rating and higher probable upside, analysts plainly believe iBio is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Surrozen has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, iBio has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market.

iBio has lower revenue, but higher earnings than Surrozen. iBio is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	80.04	-$242.03M	-$40.55	N/A
iBio	$300K	236.80	-$18.38M	-$0.58	N/A

iBio has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Surrozen's return on equity of 0.00% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-2,885.33%	N/A	-93.62%
iBio	N/A	-53.86%	-46.48%

In the previous week, Surrozen had 1 more articles in the media than iBio. MarketBeat recorded 3 mentions for Surrozen and 2 mentions for iBio. Surrozen's average media sentiment score of 0.33 beat iBio's score of 0.27 indicating that Surrozen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
iBio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

iBio beats Surrozen on 9 of the 16 factors compared between the two stocks.

How does iBio compare to Cellectis?

Cellectis (NASDAQ:CLLS) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Cellectis currently has a consensus price target of $7.00, indicating a potential upside of 105.88%. iBio has a consensus price target of $5.00, indicating a potential upside of 249.65%. Given iBio's stronger consensus rating and higher probable upside, analysts plainly believe iBio is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

iBio has a net margin of 0.00% compared to Cellectis' net margin of -102.34%. iBio's return on equity of -53.86% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
iBio	N/A	-53.86%	-46.48%

In the previous week, iBio had 1 more articles in the media than Cellectis. MarketBeat recorded 2 mentions for iBio and 1 mentions for Cellectis. Cellectis' average media sentiment score of 0.30 beat iBio's score of 0.27 indicating that Cellectis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
iBio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

iBio has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	4.29	-$67.59M	-$0.65	N/A
iBio	$300K	236.80	-$18.38M	-$0.58	N/A

63.9% of Cellectis shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 2.8% of iBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cellectis has a beta of 2.91, suggesting that its stock price is 191% more volatile than the broader market. Comparatively, iBio has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

Summary

iBio beats Cellectis on 10 of the 16 factors compared between the two stocks.

How does iBio compare to Eledon Pharmaceuticals?

iBio (NASDAQ:IBIO) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

iBio's return on equity of -53.86% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%

In the previous week, iBio and iBio both had 2 articles in the media. Eledon Pharmaceuticals' average media sentiment score of 1.35 beat iBio's score of 0.27 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eledon Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iBio currently has a consensus target price of $5.00, indicating a potential upside of 249.65%. Eledon Pharmaceuticals has a consensus target price of $9.67, indicating a potential upside of 180.19%. Given iBio's stronger consensus rating and higher probable upside, research analysts clearly believe iBio is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

iBio has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

iBio has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$300K	236.80	-$18.38M	-$0.58	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A

7.9% of iBio shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 2.8% of iBio shares are held by insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

iBio beats Eledon Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does iBio compare to Editas Medicine?

iBio (NASDAQ:IBIO) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

iBio presently has a consensus price target of $5.00, indicating a potential upside of 249.65%. Editas Medicine has a consensus price target of $5.50, indicating a potential upside of 76.85%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

iBio has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market.

7.9% of iBio shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 2.8% of iBio shares are held by company insiders. Comparatively, 3.1% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

iBio has a net margin of 0.00% compared to Editas Medicine's net margin of -157.32%. iBio's return on equity of -53.86% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-53.86%	-46.48%
Editas Medicine	-157.32%	-196.63%	-38.17%

In the previous week, Editas Medicine had 3 more articles in the media than iBio. MarketBeat recorded 5 mentions for Editas Medicine and 2 mentions for iBio. Editas Medicine's average media sentiment score of 0.64 beat iBio's score of 0.27 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Editas Medicine	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iBio has higher earnings, but lower revenue than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$300K	236.80	-$18.38M	-$0.58	N/A
Editas Medicine	$40.52M	11.79	-$160.06M	-$0.75	N/A

Summary

iBio beats Editas Medicine on 9 of the 17 factors compared between the two stocks.

Get iBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IBIO vs. The Competition

Export

Metric	iBio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$71.04M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-2.47	11.62	272.60	24.24
Price / Sales	236.80	1,338.17	618.96	99.78
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	1.59	16.80	13.05	6.20
Net Income	-$18.38M	-$12.50M	$3.47B	$348.59M
7 Day Performance	N/A	3.29%	2.09%	0.08%
1 Month Performance	2.14%	8.23%	6.64%	3.88%
1 Year Performance	N/A	55.05%	25.02%	16.98%

iBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IBIO iBio	3.0568 of 5 stars	$1.43 -2.7%	$5.00 +249.7%	N/A	$71.04M	$300K	N/A	100	News Coverage Analyst Downgrade
ARTV Artiva Biotherapeutics	2.3644 of 5 stars	$11.53 -2.1%	$39.00 +238.2%	+279.5%	$291.16M	$250K	N/A	81
SRZN Surrozen	2.8955 of 5 stars	$24.19 -3.4%	$42.00 +73.6%	+113.8%	$290.84M	$3.48M	N/A	80	Analyst Forecast
CLLS Cellectis	1.952 of 5 stars	$2.94 +1.7%	$7.00 +138.1%	+19.3%	$289.98M	$79.59M	N/A	290	Gap Down
ELDN Eledon Pharmaceuticals	2.0788 of 5 stars	$3.77 +0.5%	$9.67 +156.4%	+32.7%	$289.45M	N/A	N/A	10	News Coverage Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IBIO) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iBio (IBIO) Competitors

IBIO vs. ARTV, SRZN, CLLS, ELDN, and EDIT

How does iBio compare to Artiva Biotherapeutics?

Summary

How does iBio compare to Surrozen?

Summary

How does iBio compare to Cellectis?

Summary

How does iBio compare to Eledon Pharmaceuticals?

Summary

How does iBio compare to Editas Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO vs. The Competition

iBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iBio (IBIO) Competitors

IBIO vs. ARTV, SRZN, CLLS, ELDN, and EDIT

How does iBio compare to Artiva Biotherapeutics?

Is ARTV or IBIO more profitable?

Does the media refer more to ARTV or IBIO?

Do insiders and institutionals believe in ARTV or IBIO?

Do analysts rate ARTV or IBIO?

Which has more volatility & risk, ARTV or IBIO?

Which has better valuation and earnings, ARTV or IBIO?

Summary

How does iBio compare to Surrozen?

Do insiders and institutionals believe in SRZN or IBIO?

Do analysts recommend SRZN or IBIO?

Which has more risk & volatility, SRZN or IBIO?

Which has higher earnings & valuation, SRZN or IBIO?

Is SRZN or IBIO more profitable?

Does the media favor SRZN or IBIO?

Summary

How does iBio compare to Cellectis?

Do analysts rate CLLS or IBIO?

Is CLLS or IBIO more profitable?

Does the media prefer CLLS or IBIO?

Which has preferable earnings and valuation, CLLS or IBIO?

Do institutionals and insiders have more ownership in CLLS or IBIO?

Which has more risk & volatility, CLLS or IBIO?

Summary

How does iBio compare to Eledon Pharmaceuticals?

Is IBIO or ELDN more profitable?

Does the media refer more to IBIO or ELDN?

Do analysts rate IBIO or ELDN?

Which has more risk and volatility, IBIO or ELDN?

Which has higher earnings and valuation, IBIO or ELDN?

Do institutionals & insiders have more ownership in IBIO or ELDN?

Summary

How does iBio compare to Editas Medicine?

Do analysts rate IBIO or EDIT?

Which has more volatility and risk, IBIO or EDIT?

Do institutionals and insiders have more ownership in IBIO or EDIT?

Is IBIO or EDIT more profitable?

Does the media refer more to IBIO or EDIT?

Which has preferable valuation and earnings, IBIO or EDIT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO vs. The Competition

iBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools